Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of hepatitis C virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for…

Clarivate Epidemiology’s coverage of  hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…

China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g…

Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…

Spinocerebellar ataxia (SCA) is a heterogeneous group of rare neurodegenerative progressive disorders that primarily affects the cerebellum, and, in some cases, the spinal cord, resulting in the…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is…

Dyslipidemia is an important modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading causes of death globally. Statins continue to dominate treatment for dyslipidemia,…

NASH has the potential to be a large and lucrative therapy market owing to the disease’s prevalence and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…